JP2016522172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522172A5 JP2016522172A5 JP2016507703A JP2016507703A JP2016522172A5 JP 2016522172 A5 JP2016522172 A5 JP 2016522172A5 JP 2016507703 A JP2016507703 A JP 2016507703A JP 2016507703 A JP2016507703 A JP 2016507703A JP 2016522172 A5 JP2016522172 A5 JP 2016522172A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- deuterium
- compound
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 20
- 229910052805 deuterium Inorganic materials 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000005282 allenyl group Chemical group 0.000 claims 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- -1 alkyl carbamate Chemical compound 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 241000710781 Flaviviridae Species 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- UCDBLYHPJMMFMY-UHFFFAOYSA-N 8-bromoquinoline-4-carbonitrile Chemical compound C1=CN=C2C(Br)=CC=CC2=C1C#N UCDBLYHPJMMFMY-UHFFFAOYSA-N 0.000 claims 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010057293 West Nile viral infection Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 CC(C(N1)=O)=C(*)NC1=O Chemical compound CC(C(N1)=O)=C(*)NC1=O 0.000 description 18
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811464P | 2013-04-12 | 2013-04-12 | |
| US61/811,464 | 2013-04-12 | ||
| PCT/US2014/034021 WO2014169280A2 (en) | 2013-04-12 | 2014-04-14 | Deuterated nucleoside prodrugs useful for treating hcv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522172A JP2016522172A (ja) | 2016-07-28 |
| JP2016522172A5 true JP2016522172A5 (enExample) | 2017-06-01 |
Family
ID=50686233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507702A Ceased JP2016518359A (ja) | 2013-04-12 | 2014-04-14 | Ｈｃｖを治療するための高活性のヌクレオシド誘導体 |
| JP2016507703A Pending JP2016522172A (ja) | 2013-04-12 | 2014-04-14 | Ｈｃｖを治療するのに有用な重水素化されたヌクレオシドプロドラッグ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507702A Ceased JP2016518359A (ja) | 2013-04-12 | 2014-04-14 | Ｈｃｖを治療するための高活性のヌクレオシド誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9447132B2 (enExample) |
| EP (2) | EP2984097B1 (enExample) |
| JP (2) | JP2016518359A (enExample) |
| KR (2) | KR20160003700A (enExample) |
| CN (2) | CN105377868A (enExample) |
| AU (2) | AU2014250764A1 (enExample) |
| BR (2) | BR112015025766A2 (enExample) |
| CA (2) | CA2909270A1 (enExample) |
| ES (1) | ES2623287T3 (enExample) |
| RU (2) | RU2015148010A (enExample) |
| WO (2) | WO2014169278A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| HUE029038T2 (en) | 2012-05-25 | 2017-01-30 | Janssen Sciences Ireland Uc | Uracil spirooxetan nucleosides |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| PE20170664A1 (es) | 2014-06-06 | 2017-06-10 | Res Triangle Inst | Agonistas del receptor de apelina(apj) y usos de los mismos |
| HUE051986T2 (hu) * | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
| US20160016986A1 (en) * | 2014-07-21 | 2016-01-21 | Milind Deshpande | Stabilized nucleotides for medical treatment |
| WO2016016447A1 (en) * | 2014-07-31 | 2016-02-04 | Sandoz Ag | Synthesis of phosphoramidates |
| US10526363B2 (en) * | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| CN107108676A (zh) | 2014-09-15 | 2017-08-29 | 美迪维尔公司 | 用于制备非对映异构纯的磷酰胺酯前药的方法 |
| TWI740546B (zh) * | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| AU2015363042B2 (en) | 2014-12-15 | 2021-02-25 | Emory University | Phosphoramidates for the treatment of Hepatitis B virus |
| WO2016098123A2 (en) * | 2014-12-16 | 2016-06-23 | Laurus Labs Private Ltd | A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers |
| MA41441A (fr) * | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| IL296496B2 (en) * | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2016134053A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| WO2016134058A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
| GEP20217282B (en) | 2015-03-06 | 2021-08-10 | Atea Pharmaceuticals Inc | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| MX2018002707A (es) | 2015-09-02 | 2018-08-01 | Abbvie Inc | Derivados de tetrahidrofurano antivirales. |
| HRP20220355T1 (hr) | 2015-09-16 | 2022-05-13 | Gilead Sciences, Inc. | Postupci za liječenje infekcija coronaviridae |
| EA201890818A1 (ru) * | 2015-09-29 | 2018-09-28 | Янссен Фармасьютикалс, Инк. | Режим комбинированной терапии для лечения hcv |
| PE20190258A1 (es) | 2015-12-09 | 2019-02-25 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos |
| CN108473525A (zh) * | 2016-01-04 | 2018-08-31 | 上海长森药业有限公司 | 氘代HCV NS5b抑制剂核苷酸衍生物及其用途 |
| WO2017223421A1 (en) * | 2016-06-24 | 2017-12-28 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| US20190169221A1 (en) * | 2016-08-12 | 2019-06-06 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN107759632A (zh) * | 2016-08-19 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 一种手性磷酸酯的制备方法 |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| MX384332B (es) | 2016-09-16 | 2025-03-14 | Res Triangle Inst | Antagonistas opioides kappa de tetrahidroisoquinolina. |
| PE20190806A1 (es) | 2016-10-12 | 2019-06-10 | Res Triangle Inst | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos |
| US10696677B2 (en) | 2016-12-21 | 2020-06-30 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
| CN108276463A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一类新的化合物及其用途 |
| CN110248951B (zh) | 2017-02-01 | 2022-10-28 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| CN116036112A (zh) | 2017-03-14 | 2023-05-02 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN107987105B (zh) * | 2017-11-24 | 2019-10-01 | 无锡微色谱生物科技有限公司 | 一种可用于皮肤敷料的h2s给体化合物、海绵敷料和制备方法 |
| KR102139340B1 (ko) | 2017-12-01 | 2020-07-29 | 주식회사 엘지생활건강 | 즉시 주름 개선 및 탄력 증진용 화장료 조성물 |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| CN110835358B (zh) * | 2018-08-16 | 2022-08-05 | 上海复星星泰医药科技有限公司 | 一种索磷布韦中间体的制备方法 |
| WO2020041344A1 (en) | 2018-08-20 | 2020-02-27 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
| CN110221064A (zh) * | 2019-05-23 | 2019-09-10 | 南京农业大学 | 猪塞尼卡谷病毒elisa抗体检测方法及应用 |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| CN111233929B (zh) * | 2020-02-28 | 2023-02-28 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物的氘代物及其制备方法和用途 |
| CN118994170A (zh) | 2020-03-12 | 2024-11-22 | 吉利德科学公司 | 制备1'-氰基核苷的方法 |
| EP4132651B1 (en) | 2020-04-06 | 2026-03-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| CA3187821A1 (en) | 2020-06-24 | 2021-12-30 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| JP2024507574A (ja) | 2021-02-25 | 2024-02-20 | リサーチ トライアングル インスティテュート | アペリン受容体アゴニストとしてのヘテロアリール誘導体 |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| CN116217632A (zh) * | 2021-12-06 | 2023-06-06 | 广州谷森制药有限公司 | 一种氘代胞苷衍生物的制备方法 |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| JP2025526212A (ja) | 2022-07-21 | 2025-08-13 | アンティバ バイオサイエンシズ インコーポレイテッド | Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
| US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
| US5449664A (en) | 1988-11-21 | 1995-09-12 | Syntex (U.S.A.) Inc. | Antiviral agents |
| US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| CA2143678A1 (en) | 1992-09-10 | 1994-03-17 | Kevin P. Anderson | Compositions and methods for treatment of hepatitis c virus-associated diseases |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| EP0719273B1 (en) | 1993-09-17 | 2010-11-03 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| AU738170B2 (en) | 1996-10-16 | 2001-09-13 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
| US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
| US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
| US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
| US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
| US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
| AU753155B2 (en) | 1998-01-23 | 2002-10-10 | Kiadis Pharma Intellectual Property B.V. | Enzyme catalyzed therapeutic agents |
| US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| PY0111577A (es) | 2000-05-23 | 2017-01-02 | Idenix Cayman Ltd | Métodos y composiciones para el tratamiento del virus de la hepatitis c |
| AP2006003708A0 (en) | 2000-05-26 | 2006-08-31 | Idenix Cayman Ltd | Methods and compositions for treating flavivirusesand pestiviruses |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| JP2004533406A (ja) | 2000-10-18 | 2004-11-04 | フアーマセツト・リミテツド | ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| SI1355916T1 (sl) | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze |
| US6881831B2 (en) | 2001-05-16 | 2005-04-19 | Migenix Inc. | Nucleic acid-based compounds and methods of use thereof |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| WO2003068162A2 (en) | 2002-02-14 | 2003-08-21 | Pharmasset Ltd. | Modified fluorinated nucleoside analogues |
| KR20050006221A (ko) | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
| WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| CN1678326A (zh) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| PT1523489E (pt) | 2002-06-28 | 2014-06-24 | Centre Nat Rech Scient | Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| AU2003278904A1 (en) | 2002-09-24 | 2004-04-19 | Kornis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
| PL377287A1 (pl) | 2002-12-12 | 2006-01-23 | Idenix (Cayman) Limited | Sposób wytwarzania 2'-rozgałęzionych nukleozydów |
| AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| BRPI0419345B8 (pt) | 2003-05-30 | 2021-05-25 | Gilead Pharmasset Llc | uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| EP1680436A1 (en) | 2003-10-27 | 2006-07-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| KR100570697B1 (ko) | 2004-09-24 | 2006-04-12 | 삼성에스디아이 주식회사 | 연료 전지 시스템 및 이에 사용되는 개질기 |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| ES2569881T3 (es) | 2005-06-08 | 2016-05-12 | The University Of North Carolina At Chapel Hill | Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos |
| JP2009504704A (ja) | 2005-08-15 | 2009-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
| US7879815B2 (en) | 2006-02-14 | 2011-02-01 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| WO2008005542A2 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
| CA2657618C (en) | 2006-07-13 | 2016-10-11 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US8148349B2 (en) | 2006-12-20 | 2012-04-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| EP2097451A2 (en) | 2006-12-22 | 2009-09-09 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| KR20100014878A (ko) | 2007-01-31 | 2010-02-11 | 앨리오스 바이오파마 인크. | 2-5ａ 유도체, 및 항암제, 항바이러스제 및 항기생충제로서 이의 용도 |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
| GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2009058800A2 (en) | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| US20090176732A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma Inc. | Protected nucleotide analogs |
| US20090181921A1 (en) | 2007-12-21 | 2009-07-16 | Alios Biopharma Inc. | 2-5a analogs and their methods of use |
| WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| WO2010014134A1 (en) | 2008-07-02 | 2010-02-04 | Idenix Pharamaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AU2009279461B2 (en) | 2008-08-08 | 2014-01-23 | Scinopharm Taiwan, Ltd. | Process for making 5-azacytosine nucleosides and their derivatives |
| GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2010030858A1 (en) | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
| PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| NZ592705A (en) | 2008-12-10 | 2013-02-22 | Achillion Pharmaceuticals Inc | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| ES2527166T3 (es) | 2008-12-10 | 2015-01-21 | Achillion Pharmaceuticals, Inc. | Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral |
| CN102348712A (zh) | 2009-01-09 | 2012-02-08 | 卡迪夫大学学院顾问有限公司 | 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物 |
| EP2393815A4 (en) | 2009-02-06 | 2012-11-21 | Rfs Pharma Llc | PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS |
| AU2010226466A1 (en) | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| US20100240604A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| JO3027B1 (ar) | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
| TWI583692B (zh) * | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TW201107342A (en) | 2009-05-20 | 2011-03-01 | Chimerix Inc | Compounds, compositions and methods for treating viral infection |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| CL2011000716A1 (es) | 2010-03-31 | 2012-04-20 | Gilead Pharmasset Llc | Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c. |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| TWI515000B (zh) | 2010-04-01 | 2016-01-01 | 伊迪尼克製藥公司 | 用於治療病毒感染之化合物及醫藥組合物 |
| EA025311B1 (ru) * | 2010-07-19 | 2016-12-30 | Гайлид Сайэнсиз, Инк. | Способы получения диастереомерно чистых фосфорамидатных пролекарств |
| ES2514670T3 (es) | 2010-08-04 | 2014-10-28 | Herbert Schott | Fármacos dobles de bisfosfonato dirigidos al hueso |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| GEP20156313B (en) | 2010-09-22 | 2015-07-10 | Alios Biopharma Inc | Substituted nucleotide analogs |
| WO2012041965A1 (en) | 2010-09-29 | 2012-04-05 | Universidad Nacional De Quilmes | Process for producing dialkylphosphotriesters of nucleosides by enzymatic transesterification and deprotection thereof for producing nucleoside monophosphates |
| US9006209B2 (en) | 2010-11-10 | 2015-04-14 | Janssen Products, Lp | Uracyl spirooxetane nucleoside phosphoramidates |
| WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
| EP2655392B1 (en) | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| EP2658857B1 (en) | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| CN103403014B (zh) | 2011-01-03 | 2016-07-06 | 河南美泰宝生物制药有限公司 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
| WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
| CN103842369A (zh) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
| ES2744587T3 (es) | 2011-04-13 | 2020-02-25 | Gilead Sciences Inc | Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral |
| EP2696681B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013029761A2 (pt) | 2011-05-19 | 2017-03-21 | Univ Emory | pró-drogas de monofosfato de purina para tratamento de infecções virais |
| KR101931311B1 (ko) | 2011-05-27 | 2018-12-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | Ｈｃｖ 감염 치료에 유용한 치환된 앨리팬, 시클로팬, 헤테라팬, 헤테로팬, 헤테로-헤테라팬 및 메탈로센 |
| JP2014520772A (ja) | 2011-06-30 | 2014-08-25 | ステラ・アンパルトセルスカブ | Ｈｃｖ併用療法 |
| US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
| WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
| EP2747569A4 (en) | 2011-08-24 | 2015-07-08 | Glaxosmithkline Llc | COMBINATION TREATMENTS FOR HEPATITIS C |
| WO2013039855A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2755689A1 (en) | 2011-09-16 | 2014-07-23 | AbbVie Inc. | Methods for treating hcv |
| US8575119B2 (en) | 2011-09-23 | 2013-11-05 | Enanta Pharmaceuticals, Inc. | 2′-chloroacetylenyl substituted nucleoside derivatives |
| TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物 |
| WO2013066991A1 (en) | 2011-10-31 | 2013-05-10 | Inhibitex, Inc. | Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease |
| WO2013090420A2 (en) | 2011-12-12 | 2013-06-20 | Catabasis Pharmaceuticals, Inc. | Fatty acid antiviral conjugates and their uses |
| EP2797594A1 (en) | 2011-12-28 | 2014-11-05 | AbbVie Inc. | Methods for treating hcv |
| HK1201186A1 (en) | 2011-12-29 | 2015-08-28 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
-
2014
- 2014-04-14 BR BR112015025766A patent/BR112015025766A2/pt not_active Application Discontinuation
- 2014-04-14 US US14/252,290 patent/US9447132B2/en not_active Expired - Fee Related
- 2014-04-14 CA CA2909270A patent/CA2909270A1/en not_active Abandoned
- 2014-04-14 ES ES14722955.3T patent/ES2623287T3/es active Active
- 2014-04-14 EP EP14722955.3A patent/EP2984097B1/en active Active
- 2014-04-14 KR KR1020157032200A patent/KR20160003700A/ko not_active Withdrawn
- 2014-04-14 CN CN201480033503.7A patent/CN105377868A/zh active Pending
- 2014-04-14 EP EP14724944.5A patent/EP2984098A2/en not_active Withdrawn
- 2014-04-14 AU AU2014250764A patent/AU2014250764A1/en not_active Abandoned
- 2014-04-14 WO PCT/US2014/034018 patent/WO2014169278A1/en not_active Ceased
- 2014-04-14 WO PCT/US2014/034021 patent/WO2014169280A2/en not_active Ceased
- 2014-04-14 AU AU2014250762A patent/AU2014250762A1/en not_active Abandoned
- 2014-04-14 JP JP2016507702A patent/JP2016518359A/ja not_active Ceased
- 2014-04-14 RU RU2015148010A patent/RU2015148010A/ru not_active Application Discontinuation
- 2014-04-14 CN CN201480033500.3A patent/CN105705511A/zh active Pending
- 2014-04-14 CA CA2909273A patent/CA2909273A1/en not_active Abandoned
- 2014-04-14 US US14/252,494 patent/US20140309164A1/en not_active Abandoned
- 2014-04-14 BR BR112015025716A patent/BR112015025716A2/pt not_active IP Right Cessation
- 2014-04-14 RU RU2015148006A patent/RU2015148006A/ru not_active Application Discontinuation
- 2014-04-14 JP JP2016507703A patent/JP2016522172A/ja active Pending
- 2014-04-14 KR KR1020157032206A patent/KR20160002896A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| RU2015148006A (ru) | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv | |
| CY1122949T1 (el) | ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ | |
| JP2017527561A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| EA201992884A3 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| IL298983B2 (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| JP2019518770A5 (enExample) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2017523225A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| JP2021501756A5 (enExample) | ||
| JP2015535839A5 (enExample) | ||
| JP2016518359A5 (enExample) | ||
| AR116474A1 (es) | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV | |
| JP2015521156A5 (enExample) | ||
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| JP2018048143A5 (enExample) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| JP2006523698A5 (enExample) |